DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for obsessive-compulsive disorder — screening already-approved drugs against its 42-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleObsessive-compulsive disorder maps to a 42-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedKetamineApproved drug
Structures already discussed alongside obsessive-compulsive disorder in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
X-ray Structure of the Anesthetic Ketamine — Ketamine has a real, experimentally solved structure in complex with this target (PDB 4F8H, 2.99 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet rkedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4F8H · 2.99 Å · ligand Ketamine (RKE). Experimental structure, not a prediction.
What the evidence adds up to
In a 1988 double-blind discontinuation study, 21 patients with obsessive-compulsive disorder who had shown sustained improvement during 5 to 27 months of clomipramine treatment were assessed. Of the 18 who completed the 7-week placebo period, 16 had substantial recurrence of obsessive-compulsive symptoms, and 11 had a significant increase in depressive symptoms. The length of treatment before discontinuation was not related to the frequency or severity of symptom return. The authors concluded that prolonged drug treatment may be warranted.
A 1993 study of 49 in-patients with chronic, treatment-resistant obsessive-compulsive disorder found that in-patient exposure therapy, occasionally combined with other individually tailored interventions, produced significant clinical improvements. An average 40% reduction in rituals was seen in 31 patients (63.3%), and these gains were maintained at an average 19-month follow-up. Checking rituals were associated with better outcome, and women had a later onset and a slight tendency to better prognosis; no other predictors were found.
A 1996 study examined 58 patients with severe, treatment-resistant obsessive-compulsive disorder in a partial hospital program combining behavioural therapy, medication, and psychosocial intervention. At discharge, 71% met the criterion for successful outcome (a 25% decrease on the Yale-Brown Obsessive Compulsive Scale), and 55% finished with scores of 16 or less, indicating only mild symptoms. Most sustained improvement at 6, 12, and 18 months after discharge, and many showed further improvement with continued outpatient management. The authors called for further investigation.
A meta-analysis of 25 treatment studies from 1975 to 1991 found that clomipramine, fluoxetine, and exposure-based behaviour therapy were all significantly effective for most outcome variables, including overall severity, anxiety, and depression. Exposure was not significantly effective for reducing depressed mood. The analysis concluded that more treatment outcome studies were needed before a clearly superior treatment or combination could be statistically determined. What remains missing is large-scale, head-to-head randomised trials that stratify patients by symptom subtype, treatment history, and comorbidity, and that are funded to follow patients for years rather than weeks.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Psychiatry · 1988 · 306 citations
Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder
AbstractTo evaluate the need for maintenance drug therapy in patients with obsessive-compulsive disorder, the authors assessed 21 patients with obsessive-compulsive disorder who manifested sustained improvement during 5 to 27 months of clomipramine treatment and who agreed to participate in a double-blind discontinuation study. Of 18 patients who completed the study, 16 had substantial recurrence of obsessive-compulsive symptoms by the end of the 7-week placebo period. In addition, 11 had a significant increase in depressive symptoms. Treatment duration before discontinuation of clomipramine was not related to the frequency or severity of obsessive-compulsive or depressive symptom appearance. These findings suggest that prolonged drug treatment may be warranted for obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology · 1981 · 78 citations
The Psychopharmacological Treatment of Obsessive-Compulsive Disorder
AbstractThis article reviews the literature concerning obsessive-compulsive disorder (OCD) and its treatment with drugs. We survey the differential diagnosis of OCD and the problems involved in evaluating its severity in a research setting. Pharmacological treatment of OCD has usually involved antidepressants, especially clomipramine, with equivocal but nevertheless encouraging success. Anxiolytic and neuroleptics have also been tried, but the results are inconsistent. We discuss the implications of these findings for treatment of patients with OCD and for future research.
The British Journal of Psychiatry · 1993 · 77 citations
The Treatment of Severe, Chronic, Resistant Obsessive-Compulsive Disorder
AbstractThis study examined 49 in-patients with obsessive-compulsive disorder who were treated over three years. The patients had failed to respond to previous treatment. Treatment consisted of in-patient exposure, occasionally combined with other interventions individually tailored to the patient's specific difficulties. This resulted in significant clinical improvements and an average 40% reduction in rituals in 31 (63.3%) of these chronic patients. These gains were maintained at an average 19-month follow-up. Checking rituals were more likely to be associated with good outcome. Women had a later onset of the disorder and a slight tendency to better prognosis. No other predictors of outcome were found.
A preliminary study of partial hospital management of severe obsessive- compulsive disorder
AbstractOBJECTIVE: The study examined the effectiveness of a partial hospital treatment program combining behavioral therapy, medication, and psychosocial intervention for severe and treatment-resistant obsessive-compulsive disorder. METHODS: A total of 58 patients with a primary diagnosis of obsessive-compulsive disorder who underwent treatment in a partial hospital program were assessed at baseline, at program discharge, and at six-, 12-, and 18-month follow-ups. Obsessive-compulsive symptoms, depression, anxiety symptoms, and global functioning were rated. RESULTS: The majority of patients (71 percent) met the criterion for a successful outcome, which was a 25 percent decrease in score on the Yale-Brown Obsessive Compulsive Scale (YBOCS). Fifty-five percent finished the program with YBOCS scores of 16 or less, indicating only mild symptoms. Most of these patients sustained their improvement at six, 12, and 18 months after discharge, and many showed further improvement with continued outpatient management. CONCLUSIONS: The partial hospital treatment program for obsessive-compulsive disorder appears to be an effective intervention that should be implemented and investigated further.
Revista galega de economía: Publicación Interdisciplinar da Facultade de Ciencias Económicas e Empresariais · 2011 · 0 citations
Os mercados de carbono na Unión Europea: fundamentos e proceso de formación de prezos
AbstractThe most common effective treatments for obsessive-compulsive disorder include clomipramine, fluoxetine, and exposure-based behavior therapy. A meta-analysis was conducted on the results from 25 appropriate treatment studies (1975-1991). All three treatments were significantly effective for most of the outcome variables (overall severity, anxiety, depression). Exposure was not significantly effective for reducing depressed mood. More treatment outcome studies are needed before a clearly superior treatment or combination of treatments can be statistically determined.
Estimate of anti-obsessive properties of intravenous ketamine in OCD
AbstractThis table is drawn from a conference poster representing a reflection of the current state of research on ketamine in obsessive-compulsive disorder (OCD). <br>The literature search (conducted in 2021) has yielded nine studies that are investigating the effect of ketamine in individuals with OCD as their primary diagnosis.<br>This table displays the pooled results from all studies reporting data within the first 24h post-intravenous ketamine administration (<i>n</i> participants = 38).<br>The pooled reduction (%) in OCD scores measured post-ketamine induction is reported. Furthermore, an estimate of time required to reach the peak of effect and the duration of that effect are presented
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
